Previsão

O preço-alvo médio dos analistas é € 4,33 (+293,64%). A mediana é € 4,33 (+293,64%).

Comprar	9
Manter	0
Vender	0

Notícias Ir para o feed de notícias

Caribou reports positive phase-1 data for allogeneic CAR-T therapy Vispa-cel

Caribou released data from the phase‑1 ANTLER study of Vispa‑cel in relapsed/refractory large B‑cell lymphoma: among 27 patients treated in the second‑line setting the overall response rate was 82%, the complete response rate 67%, and median progression‑free survival 17.1 months. The safety profile showed no cases of graft‑versus‑host disease or severe immune‑effector‑cell‑associated neurotoxicity, but there was grade‑3-or-higher cytokine release syndrome, several serious infections, five cases of prolonged cytopenias and two deaths (one therapy‑related). Vispa‑cel holds multiple FDA designations and Caribou plans a registrational phase‑3 study (ANTLER‑3) with about 250 patients; data will be presented at the EHA meeting. » Mais em de.investing.com
Caribou Biosciences stock doubles after strong phase‑1 data on CB-011

Caribou Biosciences shares jumped significantly after positive phase‑1 data for the allogeneic anti‑BCMA CAR‑T therapy CB‑011 and doubled in price. In the dose‑expansion cohort, 12 patients showed an overall response rate of 92% and a complete response rate or better of 75%; 91% achieved MRD negativity. Across all dose levels CB‑011 had a manageable safety profile without GvHD, but there were serious adverse events including one treatment‑related death; a dose expansion is planned for this year, with results expected in 2026. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, CARIBOU BIOSCI. DL-,0001 registou receitas de € 1,31 mi e um ganho líquido de -€ 21,28 mi

(EUR)	junho de 2026	YoY
Receitas	1,31 mi	41,95%
Ganho bruto	1,31 mi	13,08%
Ganho líquido	-21,28 mi	53,64%
EBITDA	-23,13 mi	20,43%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 112,57 mi
Número de ações	99,18 mi
Máximo/mínimo de 52 semanas	€ 3,06 - € 1,08
Dividendos	Não
Beta	2,28
PER (PE Ratio)	-1,21
PEG (PEG Ratio)	-0,02
P/VC (PB Ratio)	1,35
P/V (PS Ratio)	12,95

Perfil da empresa

Caribou Biosciences, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich mit der Entwicklung von genom-editierten allogenen Zelltherapien zur Behandlung von hämatologischen Malignomen und soliden Tumoren in den Vereinigten Staaten und international beschäftigt. Die führenden Produktkandidaten sind CB-010, eine allogene Anti-CD19-CAR-T-Zelltherapie, die sich in der klinischen Phase 1 zur Behandlung des rezidivierenden oder refraktären B-Zell-Non-Hodgkin-Lymphoms befindet, und CB-011, eine allogene Anti-BCMA-CAR-T-Zelltherapie zur Behandlung des rezidivierenden oder refraktären multiplen Myeloms. Das Unternehmen entwickelt außerdem CB-012, eine allogene Anti-CD371-CAR-T-Zelltherapie zur Behandlung von rezidivierter oder refraktärer akuter myeloischer Leukämie, und CB-020, eine allogene CAR-NK-Zelltherapie zur Behandlung solider Tumore. Das Unternehmen arbeitet mit der AbbVie Manufacturing Management Unlimited Company zusammen, um CAR-T-Zelltherapien zu entwickeln. Das Unternehmen wurde im Jahr 2011 gegründet und hat seinen Hauptsitz in Berkeley, Kalifornien.

Nome	CARIBOU BIOSCI. DL-,0001
CEO	Rachel E. Haurwitz
Sede	Berkeley, ca EUA
Site	cariboubio.com
Setor	Bens de consumo básico
Indústria	Produtos alimentares
Entrada em bolsa	23/07/2021
Colaboradores	97